Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In addition to the BRCA1 promoter region, this work identified regions with variable methylation at multiple breast cancer susceptibility genes including PALB2 and MLH1.
|
27902704 |
2016 |
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
When evaluating by gene, the age-standardized breast cancer risks for MSH6 (SIR = 2.11; 95% confidence interval (CI), 1.56-2.86) and PMS2 (SIR = 2.92; 95% CI, 2.17-3.92) were associated with a statistically significant risk for breast cancer whereas no association was observed for MLH1 (SIR = 0.87; 95% CI, 0.42-1.83) or MSH2 (SIR = 1.22; 95% CI, 0.72-2.06).
|
29345684 |
2018 |
Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Epigenetic silencing of essential components of DNA repair pathways is a common event in many tumor types, and comprise O6-methylguanine-DNA methyltransferase (MGMT), human mut L homolog 1 (hMLH1), Werner syndrome gene (WRN), breast cancer susceptibility gene 1 (BRCA1), and genes of the Fanconi anemia pathway.
|
19671858 |
2009 |
Breast Carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We correlated the immunoreactivity of the MMR proteins hMSH2, hMLH1 and PMS2 to the immunoreaction of p53, the proliferation marker Ki67 and clinical prognosis factors such as tumor grading and staging, steroid receptor expression and hemangiosis carcinomatosa or lymphangiosis carcinomatosa in 200 samples from patients with diagnosed breast cancer.
|
17390069 |
2007 |
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
HPO |
|
|
|
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The MSI detection rate at the specific HNPCC markers varied from 0% to 10% in breast cancer, with D175250 and TP53 being the HNPCC markers most suitable for analysis of breast cancer.
|
10845276 |
2000 |
Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
An intronic mutation in MLH1 associated with familial colon and breast cancer.
|
20717847 |
2011 |
Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Breast cancer occurred in a family with hereditary nonpolyposis colon carcinoma (HNPCC; Lynch syndrome) carrying an MLH1 mutation (IVS17-3G>C).
|
15993273 |
2005 |
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Conversely, variants in the BRIP1 and RAD51C ovarian cancer risk genes; the MRE11A, RAD50, and NBN MRN complex genes; the MLH1 and PMS2 mismatch repair genes; and NF1 were not associated with increased risks of breast cancer.
|
28418444 |
2017 |
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Therefore, we performed a meta-analysis to explore the role of RARβ2, DAPK, hMLH1, p14, and p15 promoter hypermethylation in the susceptibility and clinical progression of breast cancer.
|
30572486 |
2018 |
Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
WBC DNA methylation was analysed by bisulphite pyrosequencing at ataxia telangiectasia mutated (ATM), estrogen receptor 1 (ESR1), progesterone receptor (PGR), mutL homologue 1 (MLH1), breast cancer susceptibility gene (BRCA1), secreted frizzled-related protein 1 (SFRP1), stratifin (SFN), retinoic acid receptor beta (RARB) loci and the repetitive element LINE1 in 880 SCOTROC1 trial patients [paclitaxel (Taxol)-carboplatin versus docetaxel (Taxotere)-carboplatin as primary chemotherapy for stage Ic-IV epithelial ovarian cancer].
|
24114859 |
2013 |
Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
While a colon cancer from the same individual showed MSI, the BC specimen was MSI-negative, indicating that development of the latter tumor was unrelated to MMR impairment, despite presence of a constitutional MLH1 mutation.Hum Mutat 17:521, 2001.
|
11385712 |
2001 |
Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Loss of the wild-type hMLH1 allele was detected in both breast tumors, thus suggesting that the MMR defect contributed to the development of the breast cancer.
|
23695190 |
2014 |
Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We observed two two-way SNP-SNP interactions (APEX1-rs1130409 and RPAP1-rs2297381; MLH1-rs1799977 and MDM2-rs769412) in logistic regression that conferred elevated risks for breast cancer (P(interaction)<7.3 × 10(-3)).
|
23755158 |
2014 |
Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Our data show that women with minor alleles in both MSH2 and MLH1 could be at increased breast cancer risk.
|
23852586 |
2014 |
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Thus, the present study suggests hMLH1 and RBSP3/HYA22 to be candidate TSG associated with development of both early and late-onset BC undergoing frequent genetic and epigenetic alteration and having significant prognostic implications.
|
19016758 |
2008 |
Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In a large-enrollment, sophomore-level laboratory course, groups of three to four students were assigned a gene associated with either breast cancer (brc-1), Wilson disease (cua-1), ovarian dysgenesis (fshr-1), or colon cancer (mlh-1).
|
22665589 |
2012 |
Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We observed hypermethylation of the hmlh1 gene in 43.5% of patients with primary breast cancer, of whom 66.9% had locally advanced breast cancer (stage IIIA, IIIB, and IIIC) (P < .0001).
|
18329696 |
2008 |
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Statistical analysis demonstrated that MLH1 and MSH2 deficiency may lead breast cancer progression to advanced stage, correlated with tumor focality (MLH1 P = 0.001; MSH2 P = 0.002) and chemotherapy (MLH1 P = 0.01; MSH2 P = 0.04).
|
30149959 |
2019 |
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Decrease in the expression levels of TOP2A, MSH2 and MLH1 may play significant roles in the development of chemotherapeutic resistance to etoposide in breast cancer.
|
22285073 |
2012 |
Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Carrier frequency of the MLH1 -93 variant was higher in patients who developed therapy related acute myeloid leukaemia (t-AML) (75.0%, n = 12) or breast cancer (53.3%. n = 15) after methylating chemotherapy for Hodgkin lymphoma compared to patients without previous methylating exposure (t-AML, 30.4%, n = 69; breast cancer patients, 27.2%, n = 22).
|
17959715 |
2008 |
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Our study investigates the relationship between loss of MSH2 or MLH1 function and sensitivity to the topoisomerase I and II poisons, and to the taxanes, 2 classes of cytotoxic drugs commonly used in breast cancer.
|
11477562 |
2001 |
Breast Carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Significant differences in allele frequencies between cases and controls were observed for ID3 (inhibitor of DNA binding), p = 0.05, HPN (hepsin), p = 0.009, BCAS1 (breast carcinoma amplified sequence 1), p = 0.007, CAV2 (caveolin 2), p = 0.007, EMP3 (epithelial membrane protein 3), p < 0.0001, and MLH1 (mutL homolog 1), p < 0.0001.
|
15583422 |
2004 |
Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We have identified hMLH1 mutations in 2 Amsterdam-criteria HNPCC families where both male and female gene carriers were affected with breast cancer.
|
10709098 |
2000 |
Breast Carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
After allocation of mutation status, the cumulative risk of breast cancer to 70 years in MLH1 carriers was 18.6% (95% CI 11.3 to 25.9)).
|
26101330 |
2015 |